Seriday -

: The original version of the drug was derived from human placental tissue, making it extremely difficult and expensive to produce at the time.

Developed by the biotechnology company , it was specifically designed to treat Gaucher disease , a rare genetic condition where patients lack a critical enzyme to break down fatty substances in their cells. Key Facts About Seriday Seriday

(also known as Ceredase) is a landmark in pharmaceutical history as the first enzyme replacement therapy (ERT) approved by the FDA in 1991. : The original version of the drug was

: It represented a shift in medical treatment, moving from managing symptoms to replacing the missing biological component (alglucerase) directly in the body. : It represented a shift in medical treatment,

: The success of Seriday transformed Genzyme into a biotech giant (later acquired by Sanofi for $20 billion) and paved the way for modern recombinant DNA versions like Cerezyme.